Standardized phytochemical extraction, active screening, and validated clinical protocols designed for tier-1 regulatory submissions.
In an era of intensified regulatory scrutiny (FDA NDIN, EFSA Article 13/14, NMPA Clinical Evaluation), commercial success hinges upon transitioning from empirical phytotherapy to rigorous, evidence-based clinical validation.
Global regulatory bodies require definitive pharmacokinetic (PK) and pharmacodynamic (PD) parameters. The demand for randomized, double-blind, placebo-controlled human clinical trials (RCTs) has expanded beyond prescription pharma into premium nutraceutical and functional cosmecutical verticals.
Technological advancement allows integration of decentralized clinical trials (DCTs). Utilizing wearable health-trackers and localized remote patient monitoring (RPM), CROs achieve broader demographic recruitment with improved participant retention and real-world evidence (RWE) generation.
The historical barrier between clinical CROs and manufacturing CDMOs creates formulation translation failures. Full-cycle ODM human trial manufacturers solve this by co-engineering the IP formulation directly alongside the human trial dosage protocol, guaranteeing commercial reproducibility.
Combining traditional Chinese medicine pharmacognosy with modern high-throughput biophysical screenings and Good Clinical Practice (GCP) standard human study execution.
From bio-prospecting in regional botanical habitats to multi-center human clinical trials and cGMP industrial scaling.
High-resolution screening of alkaloids, polyphenols, polysaccharides, and saponins. Leveraging deep phytochemical databases to isolate target molecules with maximized target affinity and optimized safety margins.
Explore Screening ProtocolsActive content fluctuates based on regional terroir and vegetative cycle timing. We quantify chronological and geographical variations, allowing clients to formulate high-yield, batch-consistent sourcing parameters.
View Potency AnalysisValidated test methodology is foundational for regulatory approval. We establish HPTLC fingerprinting, HPLC quantitative assays, and GC profiling to ensure unequivocal compound identification and stability evaluation.
Review Analytical ServicesOptimization of critical extraction parameters, solvent recovery, chromatography column separation, and gentle spray-drying techniques to preserve delicate thermolabile chemical complexes while maximizing volumetric yield.
Extraction Process StudiesEliminating organoleptic issues, poor biological bioavailability, and moisture instability. We formulate robust, non-degrading delivery systems, including micro-encapsulated powders, bilayer tablets, and liposomal solutions.
Formulation ArchitecturePrior to administering preparations in human cohorts, our GLP preclinical team performs rigorous acute toxicity tests (LD50), sub-chronic repeat-dose assays, bacterial reverse mutation (Ames test), and mammalian chromosomal aberration studies.
Toxicological Safety DataTarget-specific assays evaluate physiological receptor affinity, enzymatic inhibition (e.g., α-glucosidase, PDE5, COX-2), anti-inflammatory cytokine modulation (TNF-α, IL-6), and gene expression on primary human cell lines.
Cellular Testing PlatformsValidated disease models evaluating metabolic syndrome, neurodegenerative decline, gastrointestinal integrity, and immune regulation to substantiate dosing curves, mechanistic pathways, and functional efficacy profiles.
Animal Model ProtocolsTurnkey CRO orchestration: Institutional Review Board (IRB) ethics clearance, protocol authoring, cohort stratification, biostatistical analysis, and complete clinical study reports (CSR) for pharmaceutical NDAs and novel functional claims.
Human Trial DetailsSynthesizing classic herbal wisdom with molecular pharmacology. Our team refines botanical synergies, enhances ingredient stability, and designs proprietary combinations optimized for global registration hurdles.
Formulation InnovationGMP-certified extraction facilities delivering validated active pharmaceutical ingredients (APIs), standardized botanical tinctures, concentrated viscous pastes, and crystallized chemical fractions ready for industrial integration.
Order Raw ActivesEnd-to-end commercial manufacture: softgels, vegetarian hard capsules, scored tablets, direct-dissolving micro-granules, and oral health liquids produced under strict Class 100,000 cleanroom protocols with absolute NDA protection.
Finished Dosage ContractTailoring clinical study design to match distinct regional consumer genetics, gut microbiome profiles, and regional regulatory bodies.
Designed for urban populations facing escalating Type-2 metabolic challenges. We configure double-blind human trials measuring postprandial blood glucose, HbA1c, insulin sensitivity indices, and long-term lipid homeostasis backed by continuous glucose monitors (CGM).
Evaluating botanical adaptogens and nootropics on high-stress demographic segments. Protocol tracking focuses on polysomnography (sleep architecture), salivary cortisol fluctuations, cognitive processing metrics, and systemic HRV markers.
Validating ingestible beauty and topical phytochemicals through high-precision biophysical dermal tools (Corneometer, Tewameter, Visia-CR complex skin imaging) tracking transepidermal water loss (TEWL), wrinkle topography, and dermal collagen synthesis.
How AI integration, biomarker omics, and synthetic biology are transforming ODM human clinical research through 2030.
Utilizing molecular docking algorithms and machine learning models to predict active compound bio-receptivity, metabolism, and safety flags prior to wet-lab clinical synthesis.
Incorporating deep metagenomics, metabolomics, and single-cell RNA sequencing into human trial endpoints to pinpoint exact molecular biological changes.
Eliminating geographical barriers through continuous digital biomarker monitoring, mobile e-Consent, and cloud-synchronized biometric telemetry.
Manufacturing specialized micro-fluidic nano-carriers and enteric-coated formulations directly tuned to an individual's validated clinical response profiles.
Our institutional network includes state key laboratories, Class III Grade A clinical medical institutions, and listed pharmaceutical conglomerates.
Addressing intellectual property barriers, trial compliance, international dossier translation, and manufacturing batch scaling.
Traditional CROs manage regulatory logistics and patient visits without internal pilot plants or deep botanical extraction expertise. MedGence combines full CRO clinical trial operations with proprietary CDMO pilot plants and industrial extraction units. This single-source integration prevents knowledge loss between lab trials and commercial mass production.
All contract research is conducted under legally binding bilateral NDAs. The client retains 100% ownership of clinical study master files (TMF), analytical chromatography data, process parameters, and resulting patent portfolios. Our entrusted research framework guarantees complete IP firewalls between client projects.
Yes. Beyond formal Phase I–IV pharmaceutical new drug applications (NDAs), we routinely execute agile, randomized, double-blind, placebo-controlled human efficacy trials (n=30 to n=120 cohorts) specifically tailored to substantiate dietary supplement functional claims for US FDA, EFSA, and APAC health regulatory authorities.
Our analytical suites leverage high-performance thin-layer chromatography (HPTLC), reversed-phase HPLC coupled with DAD/ELSD detectors, gas chromatography-mass spectrometry (GC-MS), LC-MS/MS, and high-dimensional chemical fingerprinting to quantify marker actives and limit heavy metal and pesticide residue levels.
We directly scale formulations from clinical batch production to commercial cGMP volume. Available forms include softgels, vegetable hard capsules, enteric-coated tablets, oral functional elixirs, effervescent powders, and micro-granules packaged in blister packs, sachets, or HDPE containers.
Our trial workflows strictly comply with ICH-GCP E6(R2) standards. We implement 21 CFR Part 11 compliant Electronic Data Capture (EDC), independent Data Safety Monitoring Boards (DSMB), continuous on-site clinical research associate (CRA) monitoring, and third-party biostatistical audit trails.
Accelerate your time-to-market with established preclinical protocols and validated clinical study blueprints.
Whether structuring an exploratory pilot human cohort or developing a multi-center Phase III clinical dossier, MedGence provides end-to-end scientific rigor, analytical precision, and manufacturing reliability.